News

China reports surge in asymptomatic COVID-19 cases

China reported increasing number of asymptomatic cases of coronavirus disease (COVID-19) sparking concerns of second wave of infection.
Despite the draconian measures imposed, China is struggling to contain the spread of imported and asymptomatic patients who are not showing symptoms that they are carrying the virus.
National Health Commission registered 78 new asymptomatic COVID-19 cases on Sunday, higher than the reported 47 on Saturday.
RELATED STORY: China lifts lockdown on Hubei near the 1st epicenter of COVID-19
Hubei province, where the virus originated, accounts for almost half of the new asymptomatic cases, Reuters reported.
There are 705 individuals with asymptomatic cases who are under treatment in mainland China.
This poses concern to the Hubei’s capital Wuhan, which prepares to waive the travel restriction to residents of the city on April after 3 months of lockdown.
Wuhan has recalled the “epidemic-free” status of 45 residential compounds due to the emergence of asymptomatic cases and for other unspecified reasons, state-run Xinhua News Agency reported.
The “Epidemic-free” certificate status allows people living in a compound in Wuhan to leave their homes for two hours at a time.
READ ON: ‘Getting back to normal’: Workers in China starting to return to work
China said most of the imported cases are returning Chinese nationals abroad, prompting the Chinese government to shut its borders as well as international flights.
Health authorities reported 39 new COVID-19 cases, with 38 of which identified as imported cases on Monday.
The overall confirmed cases on the mainland China had reached 81,708 by Sunday, including 1,299 patients who were still being treated, 77,078 patients who had been discharged after recovery and 3,331 people who died of the disease.

Staff Report

The Filipino Times is the chronicler of stories for, of and by Filipinos all over the world, reaching more than 236 countries in readership. Any interesting story to share? Email us at [email protected]

Related Articles

Back to top button
Close